UNRESECTABLE MALIGNANT SOLID NEOPLASM
Clinical trials for UNRESECTABLE MALIGNANT SOLID NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE MALIGNANT SOLID NEOPLASM trials appear
Sign up with your email to follow new studies for UNRESECTABLE MALIGNANT SOLID NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Early trial tests new drug combo for Tough-to-Treat cancers
Disease control OngoingThis early-stage study aims to find the safest and most effective dose of a new drug, M6620, when given with the chemotherapy drug irinotecan. It is for adults with advanced solid tumors, like certain colorectal, pancreatic, or lung cancers, that have spread or cannot be removed …
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Experimental pill aims to starve advanced cancers by cutting off their fuel supply
Disease control OngoingThis trial is testing whether a pill called telaglenastat can slow or stop the growth of advanced solid tumors that have specific genetic mutations. The drug works by blocking a key nutrient (glutamine) that some cancer cells need to grow. The study is for adults with metastatic …
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Scientists test Double-Punch immune therapy for tough cancers
Disease control OngoingThis early-stage study is testing a new combination of two immunotherapy drugs, pembrolizumab and interleukin-12, for people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find the safest dose and understand the side effects. Re…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Personalized immune cells tested to fight five tough cancers
Disease control TerminatedThis early-stage study aimed to test the safety and early effectiveness of a personalized cell therapy called STIL101. The therapy involved growing a patient's own cancer-fighting immune cells (T-cells) from a tumor sample in a lab and then infusing them back. It was designed for…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New combo attack targets Cancer's genetic weakness
Disease control OngoingThis early-phase trial is testing a combination of two drugs, avelumab and M6620, for people with advanced solid tumors that have spread or cannot be removed by surgery. The treatment is specifically for cancers with flaws in certain genes responsible for fixing DNA damage inside…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New drug duo tested in Tough-to-Treat cancers
Disease control TerminatedThis early-stage study is testing the safety and best dose of a new two-drug combination (ZEN003694 and binimetinib) for people with advanced solid tumors that have specific genetic changes in the RAS pathway, including triple-negative breast cancer. The trial aims to see if the …
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Scientists test booster shot for Cancer-Killing cells
Disease control OngoingThis early-stage study is testing the safety of adding a drug called atezolizumab after a personalized immune cell therapy for patients with advanced blood or solid tumor cancers. The goal is to see if the drug helps the transferred immune cells survive longer and fight the cance…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New Two-Pronged attack on advanced cancers shows promise in early trial
Disease control OngoingThis early-stage trial is testing a new combination of three drugs for patients with advanced solid tumors that have spread and have specific genetic changes (PIK3CA or PTEN). The goal is to see if adding a drug called copanlisib to standard immunotherapy drugs (nivolumab and ipi…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Scientists test new drug duo to fight tough cancers
Disease control OngoingThis early-stage study is testing a new combination of two drugs, sonidegib and pembrolizumab, for people with advanced solid tumors that have spread. The main goals are to find the safest dose of the combination and see if it helps shrink or control the cancer. The study is enro…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
Scientists test new drug duo to starve and stop tough cancers
Disease control OngoingThis early-stage study is testing a combination of two oral drugs, cediranib and selumetinib, in patients with advanced solid tumors that cannot be removed by surgery and have no standard treatment options. The main goals are to find the safest dose and understand the side effect…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Scientists test new combo attack on Tough-to-Treat cancers
Disease control TerminatedThis early-stage trial is testing the safety and best dose of a two-drug combination for people with advanced solid tumors that have a specific gene change called HER2. The study combines a targeted chemotherapy drug (trastuzumab deruxtecan) with a pill that blocks cancer growth …
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 24, 2026 12:03 UTC
-
New hope for tough cancers: trial tests drug duo to outsmart resistant tumors
Disease control TerminatedThis study is testing whether adding a targeted drug called ipatasertib to a standard chemotherapy (paclitaxel) can help control advanced solid tumors that have specific genetic changes and have stopped responding to similar chemotherapy drugs. It aims to see if this combination …
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
Scientists test Triple-Threat attack on Tough-to-Treat cancers
Disease control OngoingThis study is testing a new three-part treatment for people with advanced cancers that have spread. It combines a new pill (peposertib), an immunotherapy drug (avelumab), and a short, high-dose course of radiation. The goal is to see if this combination can better control cancer …
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
Double attack on tough cancers: early trial tests combo for patients out of options
Disease control OngoingThis early-stage trial is testing a combination of two drugs, niraparib and dostarlimab, for people with advanced breast, ovarian, pancreatic, or related cancers that have a specific genetic change (BRCA mutation) and have stopped responding to standard treatments. The goal is to…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
Scientists test new drug timing to outsmart resistant cancers
Disease control OngoingThis early-phase study is testing a new way of giving two cancer drugs—one after the other instead of together—to see if it is safe and tolerable for people with advanced solid tumors that have stopped responding to standard treatments. The trial aims to find the best dose and se…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC
-
Early trial aims to tame tough cancers with Two-Pronged attack
Disease control OngoingThis early-stage study is testing a new drug, ALRN-6924, combined with a standard chemotherapy (paclitaxel) for people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find the safest and most effective dose of this combination an…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 13, 2026 15:06 UTC
-
Scientists test new two- and Three-Drug cocktails against tough cancers
Disease control OngoingThis early-phase study is testing the safety and best doses of combining the cancer drug copanlisib with immunotherapy drugs (nivolumab alone or with ipilimumab). It involves 64 adults with advanced solid tumors or lymphoma that have progressed after standard treatments. The goal…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 11, 2026 14:52 UTC
-
New drug duo targets 'Undruggable' cancer mutations
Disease control OngoingThis study is testing the safety and effectiveness of combining two oral drugs, trametinib and navitoclax, for patients with advanced solid tumors that have spread and have specific KRAS or NRAS genetic mutations. The goal is to find the best dose and see if the combination can s…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 09, 2026 14:25 UTC
-
Scientists test Triple-Threat drug cocktail against advanced cancers
Disease control OngoingThis early-stage trial is testing a combination of three drugs—copanlisib, olaparib, and durvalumab—in patients with advanced solid tumors that have spread or cannot be removed by surgery. The main goal is to find the safest and most effective dose of this combination for people …
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Feb 25, 2026 15:07 UTC
-
Scientists probe how new cancer drug battles tumors
Knowledge-focused OngoingThis is an early, small study to understand how the drug DS-8201a works in the body of patients with advanced HER2-positive cancers. Researchers are giving the drug to 62 patients and taking small tumor samples before and after treatment to see how it affects cancer cells and the…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:14 UTC